Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Charles River Laboratories Cleveland, Inc.
EIR
•Charles River Laboratories Cleveland, Inc.•July 16, 2010

Charles River Laboratories Cleveland, Inc. – FDA EIR, Jul 16, 2010

Record Details

An FDA inspection of Chantest Inc., a Cleveland-based in-vitro non-clinical test facility specializing in drug safety and discovery services, was conducted from July 12-16, 2010. The unannounced inspection, directed by GLP regulations (21 CFR Part 58), focused on a data audit of pharmacology safety data related to human drugs. The primary violation documented on FDA Form 483 concerned inadequate protocol documentation. Specifically, for Study (b)(4), a critical change in test article concentration was implemented in a Phase I assay without a documented and approved protocol amendment or deviation. Inspectors also noted instances where protocol amendments for other studies were signed after the effective date, indicating changes were executed before formal approval by the study director. Furthermore, the inspection highlighted an outdated master schedule with several studies pending finalization for years, and concerns were raised about the data security and audit trail capabilities of the firm's (b)(4) software system. In response, Chantest Inc. issued a report amendment and protocol deviation for the identified study during the inspection and stated they implemented new procedures to prevent recurrence. The company also closed nine outstanding studies and committed to updating its master schedule. Critically, Chantest Inc. provided a written commitment to the FDA outlining plans to enhance data security for its (b)(4) software system within (b)(4) days, including (b)(4).

Company
Charles River Laboratories Cleveland, Inc.
Inspection date
July 16, 2010
Product type
drugs
People
  • Zhou Chen (issuing_officer)
  • Michael Fraifogl (company_representative)
  • Jennifer A. Scocos (company_representative)
  • Karen M. Kondas (investigator)
  • Jessica Brimecombe (company_representative)
View Company Profile

ID · 2d5828dc-e2ff-4d78-9ccb-8f0fd8622dd7

Violation Codes1
21 CFR 58.120(b)

Full citation text and observation details available on the Dashboard.

Other documents for Charles River Laboratories Cleveland, Inc.
  • EIR - 2020-02-19February 19, 2020

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Charles River Laboratories Cleveland, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.